Clinical Trials Logo

Perinatal Asphyxia clinical trials

View clinical trials related to Perinatal Asphyxia.

Filter by:

NCT ID: NCT02071160 Completed - Perinatal Asphyxia Clinical Trials

Melatonin for Neuroprotection Following Perinatal Asphyxia

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to examine the effect of combining melatonin to whole body cooling on the brain injury and outcome of neonates following perinatal asphyxia.

NCT ID: NCT02002039 Completed - Perinatal Asphyxia Clinical Trials

Neuroprotective Role of Erythropoietin in Perinatal Asphyxia

Start date: June 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Whether Erythropoietin improves the neurological outcomes of neonates with perinatal asphyxia.

NCT ID: NCT01626924 Terminated - Perinatal Asphyxia Clinical Trials

A Study of 2-Iminobiotin in Neonates With Perinatal Asphyxia

Start date: June 2012
Phase: Phase 2
Study type: Interventional

In case of insufficient oxygen supply to the brain of a newborn child (perinatal asphyxia), toxic compounds will be formed. These toxic compounds will damage the cells of the brain. 2 Iminobiotin (2 IB) is an investigational medicinal product that is related to vitamin B7. From studies in animals it has been shown that 2-IB may prevent the formation of the toxic compounds. Also it has been shown to be safe in in studies in juvenile animals and in healthy, adult male volunteers. The doctors hope that this will prevent (part of) the potential brain damage that may result from lack of oxygen to the brain. This study is the first study in the target population: newborn with moderate to severe oxygen shortage during birth. In this study the investigators evaluate short term efficacy, safety and pharmacokinetics of 2-Iminobiotin. In the follow-up phase the investigators evaluate the long term efficacy and safety. The study hypothesis is that 2-Iminobiotin will help to decrease the brain damage after oxygen shortage and is indeed safe. The brain damage will be measured both in the first week and during the first two years of life. The study was designed as a study with two parts an open label pilot part (6 patients) and a double-blind randomised part (60 patients). Due to lack of recruitment it was decided in September2014 to stop recruitment after the open label pilot part of the study (6 patients).

NCT ID: NCT00624871 Completed - Clinical trials for Hypoxic Ischemic Encephalopathy

Ascorbic Acid and Ibuprofen in Infants With Hypoxic Ischemic Encephalopathy

Start date: April 2004
Phase: N/A
Study type: Interventional

Oxygen radicals and inflammation are important causes for brain injury in neonates following perinatal asphyxia. Animal studies demonstrated potential benefits to the brain when using both of vitamin C and ibuprofen. The efficacy of these 2 drugs when combined in protecting the human brain has not been studied. We aimed in this study to test the hypothesis that a combination of anti-oxidants (vitamin C) and anti-inflammatory (ibuprofen) drugs can decrease the brain injury in perinatal asphyxia and improve outcomes when given to infants immediately after birth.

NCT ID: NCT00062452 Completed - Clinical trials for Infant, Premature, Diseases

Esophageal Motility and Airway Defenses Among Infants

Start date: May 2002
Phase: N/A
Study type: Observational

Feeding difficulties and airway related consequences contribute significantly to the infant mortality and morbidity. Some of these problems may be dependent on neural control and muscular function. Prematurity, congenital anomalies and perinatal depression represent three important conditions in infants, that may have feeding and airway difficulties.Development of motility of the foregut and the adaptation during normal and disease in developing infants is unclear.